NCT01409200View on ClinicalTrials.gov

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

March 26, 2012

Primary Completion Date

January 15, 2026

Study Completion Date

January 15, 2026

Conditions
Metastatic Malignant Neoplasm in Lymph NodeProstate Ductal AdenocarcinomaStage III Prostate Adenocarcinoma AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
DRUG

Antiandrogen Therapy

Given per standard of care

DRUG

Axitinib

Given PO

PROCEDURE

Radical Prostatectomy

Undergo radical prostatectomy

PROCEDURE

Regional Lymph Node Dissection

Undergo pelvic lymph node dissection

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER